Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roivant Sciences

https://roivant.com/

Latest From Roivant Sciences

Finance Watch: Structure Launches Third And Largest US Biopharma IPO Of 2023

Public Company Edition: Structure Therapeutics’ upsized initial public offering raises $161.1m, surpassing proposed terms for up to $134.3m. Also, Pliant capitalizes on good data with a $287.5m follow-on offering, while Magenta seeks strategic alternatives and Instil reveals more job cuts.

Financing Business Strategies

Roivant Is Striving Towards New Standards Of Care

With numerous highly anticipated data readouts due over 2023, the spotlight is on Roivant like never before. CEO Matt Gline enlightens In Vivo on the firm’s ‘vant’ subsidiaries, its in-house drug development strategies and the future of its Vtama psoriasis treatment.

Companies Business Strategies

Finance Watch: SPAC Deals Stumble, Layoffs Continue As Valuations Struggle To Recover

Aesther Healthcare Acquisition extended the deadline to merge with Ocean Biomedical, while Intrinsic Medicine no longer plans to go public by merging with a SPAC. In restructuring news, Otonomy begins liquidation, Celyad cuts last clinical program with cash running out and Clovis files for bankruptcy.

Financing Restructuring

Myovant Accepts Higher Sumitovant Offer In Deal That Values It At $2.9bn

Sumitovant, a Sumitomo subsidiary, will pay $27 per share for the 48% of Myovant shares it does not already own, for a deal value of $1.7bn, up from a $22.75-per-share bid in early October.

M & A Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Altavant Sciences
    • Alyvant
    • Aruvant Sciences
    • Axovant Sciences
    • Cyotvant Sciences
    • Datavant
    • Dermavant Sciences
    • Enzyvant
    • Genevant
    • Immunovant Sciences
    • Metavant Sciences
    • PhaseRx
    • Respivant
    • Roivant Health
    • Roivant Neurosciences Ltd
    • Roivant Pharma
    • Roivant Sciences Ltd.
    • Inc.
    • Sinovant Sciences
    • Sumitovant Biopharma Ltd.
    • Valor Biotechnology
    • Axovant Gene Therapies Ltd.
    • Kinevant Sciences
UsernamePublicRestriction

Register